Meeting
2015 Genitourinary Cancers Symposium
Overall survival (OS) in renal cell carcinoma (RCC) before and after the introduction of targeted therapies (TTs): A Norwegian population-based study (2000–2011).
Authors
Olbjorn Klepp
Department of Oncology, Ålesund Hospital
Olbjorn Klepp , Tom Børge Johannesen , Jan Oldenburg , Knut Martin Torgersen , Jan Kowalski , Oddvar Solli , Rickard Sandin , Christian Beisland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 443)
DOI
10.1200/jco.2015.33.7_suppl.443
Abstract #
443
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
First Author: Angela Strambi
Poster
2012 ASCO Annual Meeting
Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.
First Author: Giuseppe Procopio
Poster
2012 Genitourinary Cancers Symposium
Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000-2008).
First Author: Ulrika Harmenberg
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst